Claims for Patent: 7,014,990

Summary for Patent: 7,014,990

Title:	Machine perfusion solution for organ and biological tissue preservation
Abstract:	Machine perfusion solutions for the presentation of organs and biological tissues prior to implantation, including a prostaglandin having vasodilatory, membrane stabilizing, platelet aggregation prevention upon reperfusion, and complement activation inhibitory properties, a nitric oxide donor, a glutathione-forming agent, and an oxygen free radical scavenger.
Inventor(s):	Polyak; Maximilian (Glenmoore, PA), Arrington; Ben O\'Mar (East Stroudsburg, PA)
Assignee:	Arrington; Ben O\'Mar (East Stroudsburg, PA)
Application Number:	09/976,805
Patent Claims:	1. The machine perfusion solution of claim 1 wherein the solution comprises about 1,000 micrograms/L prostaglandin E1, about 10 mg/L nitroglycerin, and about 0.2 mg/L N-acetylcysteine, further comprising: about 60 100 mM sodium gluconate; about 20 30 mM KH.sub.2PO.sub.4; about 3 8 mM magnesium gluconate; about 3 8 mM adenine; about 3 8 mM ribose; about 0.3 0.8 mM CaCl.sub.2; about 8 15 mM HEPES; about 8 15 mM glucose; about 15 50 mM mannitol; and about 45 55 g/L pentastarch. 2. The machine perfusion solution of claim 1 wherein the solution comprises about 1,000 micrograms/L prostaglandin E1, about 10 mg/L nitroglycerin, and about 0.2 mg/L N-acetylcysteine, further comprising: about 80 mM sodium gluconate; about 25 mM KH.sub.2PO.sub.4; about 5 mM magnesium gluconate; about 5 mM adenine; about 5 mM ribose; about 0.5 mM CaCl.sub.2; about 10 mM HEPES; about 10 mM glucose; about 30 mM mannitol; and about 50 g/L pentastarch. 3. The machine perfusion solution of claim 1 or 2 further comprising at least one of distilled water and deionized water. 4. An organ or biological tissue preservation aqueous machine perfusion solution comprising: about 1,000 micrograms/L prostaglandin E1; about 10 mg/L nitroglycerin; about 0.2 mg/L N-acetylcysteine; about 40 160 mM sodium gluconate; about 10 50 mM KH.sub.2PO.sub.4; about 1 15 mM magnesium gluconate; about 1 15 mM adenine; about 1 15 mM ribose; about 0.1 2 mM CaCl.sub.2; about 1 30 mM HEPES; about 1 30 mM glucose; about 10 100 mM mannitol; about 40 60 g/L pentastarch; and about 700 900 mL sterile water. 5. A method for preserving a cadaveric organ or biological tissue, wherein the organ or tissue is a kidney or tissue from a kidney, comprising: pouring the machine perfusion solution of claim 1, 2, 3 or 4 into a chamber that mimics at least one of a deep hypothermic environment and physiological environment; circulating the machine perfusion solution continuously through the chamber; inserting the at least one of a cadaveric organ and tissue into the chamber; and flushing the at least one of a cadaveric organ and tissue with the machine perfusion solution. 6. The method of claim 5 wherein the flushing comprises: infusing the solution through vasculature of the at least one of a cadaveric organ and tissue. 7. The method of claim 5 wherein the flushing comprises: infusing the solution over or through an avascular biological substance of the at least one of a cadaveric organ and tissue to maintain viability during an ex vivo period. 8. The method of claim 5 further comprising: monitoring parameters of the at least one of a cadaveric organ and tissue. 9. The method of claim 5 further comprising: exsanguinating the at least one of a cadaveric organ and tissue; and replacing the machine perfusion solution with at least blood to return the at least one of a cadaveric organ and tissue to a normothermic condition. 10. A method of preparing an organ or biological tissue preservation machine perfusion solution of claim 1, 2, 3 or 4 comprising: providing a solution with sterile water; adding the sodium gluconate, potassium phosphate, adenine, ribose, calcium chloride, pentastarch, magnesium gluconate, HEPES, glucose, mannitol, and insulin to the solution; and mixing the prostaglandin E1, nitroglycerin and N-acetylcysteine into the solution. 11. The method of claim 10 further comprising: mixing the solution until all components are dissolved. 12. The method of claim 10 further comprising: infusing the pentastarch under pressure through a dialyzing filter; centrifuging the prostaglandin E1 under hypothermic conditions; and filtering the centrifuged prostaglandin E1.

Details for Patent 7,014,990

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2020-10-13